deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02151448

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies

Sponsor: David Bartlett

Conditions Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface Malignant Peritoneal Mesothelioma Peritoneal Carcinomatosis
Interventions Celecoxib DC vaccine Interferon Alfa-2b rintatolimod
Updated 16 times since 2017 Last updated: Jul 6, 2020 Started: Jul 31, 2014 Primary completion: Feb 18, 2019 Completion: Feb 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface and Malignant Peritoneal Mesothelioma, this trial is completed. The trial is conducted by David Bartlett and has accumulated 16 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Mar 2020 — Aug 2020 [monthly]

    Completed PHASE1_PHASE2

  3. Feb 2020 — Mar 2020 [monthly]

    Completed PHASE1_PHASE2

  4. May 2019 — Feb 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • David Bartlett
  • National Cancer Institute (NCI)
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations